In December 2008, AMD3100 was approved by the FDA for hematopoietic stem and progenitor cell (HSPC) mobilization in combination with granulocyte colony-stimulating factor (G-CSF) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma undergoing autologous bone marrow transplantation. This evidence concerns the gene CSF3 and non-Hodgkin lymphoma.